The 34th ECNP Congress will take place on October 2-5 in Lisbon. This is the most important European scientific meeting dedicated to brain research for disease. Each year, this event attracts over 5,000 psychiatrists, neurologists and psychologists from around the world.

During the 34th ECNP Congress, posters will be presented. Posters by Sylwia Janowska - Clinical Development Leader, Mikołaj Matłoka - Research Group Leader - Neuropsychiatric Diseases were honored with the ECNP Excellence Award.

Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration

M. Matloka1, A. Gajos-Draus1, I. Majkowska1, S. Kokhanovska1, P. Pankiewicz1, S. Janowska1, K. Wójcik1, M. Wieczorek1, J. Pieczykolan1,

1R&D Centre, Celon Pharma SA, Marymoncka 15, 05-152 Kazun Nowy, Poland

Safety assessment of esketamine administered via dry powder inhaler in patients with treatment-resistant major depression

S. Janowska1, M. Wieczorek1, P. Gałecki 2,

1Celon Pharma SA, R&D Centre, Łomianki, Poland

2 Department of Adult Psychiatry, Medical University of Łódź, Łódź, Poland

Safety assessment of esketamine administration via dry powder inhaler in patients with treatment-resistant bipolar depression

M. Wieczorek1, S. Janowska1, P. Gałecki2

1Celon Pharma SA, R&D Centre, Łomianki, Poland

2 Department of Adult Psychiatry, Medical University of Łódź, Łódź, Poland

Attachments

  • Original document
  • Permalink

Disclaimer

Celon Pharma SA published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 11:51:06 UTC.